Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.

Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q33380807

Q33380807

about

Vaccine adjuvants as potential cancer immunotherapeutics Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands Safety of Toll-like receptor 9 agonists: a systematic review and meta-analysis.The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis.Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects.Toll-like receptor agonists in cancer therapy.Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.Accelerated wound healing mediated by activation of Toll-like receptor 9 Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers.Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.CpG and non-CpG oligodeoxynucleotides directly costimulate mouse and human CD4+ T cells through a TLR9- and MyD88-independent mechanism Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis.Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come Intrapulmonary Delivery of CpG Microparticles Eliminates Lung Tumors.Trial Watch: Experimental Toll-like receptor agonists for cancer therapy Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia Immunotherapy of cancer in 2012.Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality A guanidine-rich regulatory oligodeoxynucleotide improves type-2 diabetes in obese mice by blocking T-cell differentiation.Effects of CpG oligodeoxynucleotide 1826 on acute radiation-induced lung injury in mice Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning.CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.TLR agonists: our best frenemy in cancer immunotherapy Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies.Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers Toll-like receptors in prostate infection and cancer between bench and bedside Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.TLR9 activation coupled to IL-10 deficiency induces adverse pregnancy outcomes.Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation.Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer.Immunoregulation of GVHD by triggering the innate immune system with CpG.Toll-like receptor 9 agonists as cancer therapeutics.Stimulating natural killer cells to protect against cancer: recent developments.

P2860

Q26752522-D4F08354-1433-4E46-B5C6-B817644AC331 Q28972540-AF33B776-9A02-4D62-BB88-2AF23C279B03 Q33413438-F1B20A76-ED23-435E-BF44-A3D6FCBA86A7 Q33434828-812AFD36-E12E-4261-B4B8-6DF9EEA9EC70 Q33801802-87FB4433-84F4-4EBF-8FB4-E665E11D3DC8 Q33918509-544EFBA8-B135-46B9-94DE-8ED0E8E14587 Q33960866-5632227E-FD6D-454F-89E9-8171865E909C Q34440785-FA7914DE-2F2D-4792-B920-3852054EF627 Q34613585-3D10EC4B-645B-48AC-BC0C-BB2866B25EB7 Q34619324-CA27762B-2AFE-447D-8285-2218CF6EC6EF Q34644769-9745D794-9167-41A4-AAC2-09A4F2F5CF75 Q35018021-69B30E5C-D14F-4F30-A533-23C912856582 Q35058213-483FC4F1-D945-4E9B-AFDE-0A78050DD365 Q35204579-CC25C392-6AC3-4FAC-9629-9611088FF1BE Q35466199-9863BB5B-68D9-4B68-8253-B1482E521346 Q35624884-EEF49DF2-B723-41DB-851B-17A8D13D5105 Q36132725-32B0B19A-E792-45A6-8C7A-1AF9253648FD Q36194849-2626CD4D-FCCB-48BA-8287-7E09D6F0417D Q36222910-6A29D6CD-71DC-4EDC-9077-B3DAFD16C5D1 Q36243536-945EEBBC-E968-452E-9AD2-6A09A2B53123 Q36326572-9C49D0BE-5FE8-4916-9483-BB6816F316CE Q36379556-16BE6DC2-4F39-4B29-99EB-632A41CC1343 Q36538093-0B14198D-2789-4AB7-B596-07B49CFFB17F Q36583710-8D512F7E-8609-4583-8D0D-D6E090610F2F Q36600960-0ED4049C-62CE-4DC2-8A68-3B823B3B4260 Q36607439-058555EA-298A-4287-B509-0530AFD095FB Q36771989-D83C22E9-2ABE-46CA-A128-F043AEA5B730 Q36850457-657C27A4-DEE5-45AB-B785-D534B409073E Q36946100-A3876C91-5088-4CF8-8129-235487A3C4D9 Q37092663-3FA8DD82-3426-4490-9862-DA6C3CF1AFF8 Q37291780-9E60A63C-1657-4884-8B5F-8DD93D8CD837 Q37295411-9496F358-F0DB-435F-A9E0-5AAB349F6E75 Q37354301-33149D82-FC6B-4D87-A747-0E9757B3469D Q37447389-1C5533E7-1342-4A36-AE13-1C09AE0B881E Q37579650-8F127719-7F1D-4B33-9882-043C154AEBDF Q37594369-75773DD1-D794-4FC1-88D1-4DBBB3F65E04 Q37739809-74F3E092-7F79-446A-BEA3-BE27099D30DC Q37810081-5D7D165A-C538-445F-9437-70BB1E711D4B Q37831323-1A005B5B-67BE-4266-A31B-F320324F1C6D Q37877269-3FDAA973-AF10-4463-A178-67D05D44B913

P2860

Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q33380807

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu